<DOC>
	<DOCNO>NCT01857726</DOCNO>
	<brief_summary>The aim study compare efficacy transarterial chemoembolization adriamycin transarterial chemoembolization adriamycin/transarterial chemoinfusion cisplatin combination advance hepatocellular carcinoma portal vein invasion .</brief_summary>
	<brief_title>Comparison TACE Versus TACE/TACI Combination Advanced Hepatocellular Carcinoma With Portal Vein Invasion</brief_title>
	<detailed_description>Potentially curative treatment hepatocellular carcinoma ( HCC ) include surgical resection , liver transplantation , local ablative therapy . However , HCC patient diagnose advanced stage Korea . Especially , HCCs portal vein invasion unresectable suitable curative therapy . For patient , optimal treatment remain largely controversial . As palliative treatment , benefit transarterial chemoembolization ( TACE ) show patient unresectable HCC without portal vein invasion several trial . In patient main portal vein invasion , TACE theoretically contraindicate potential risk hepatic failure result ischemia TACE . However , recent study reveal TACE could safely perform patient . The aim study compare efficacy transarterial chemoembolization ( TACE ) adriamycin transarterial chemoembolization adriamycin/transarterial chemoinfusion ( TACI ) cisplatin combination advance hepatocellular carcinoma portal vein invasion .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Patients clinical histological diagnosis HCC base guideline AJCC Patients advance HCC invasion major branch ( e ) portal vein arterial phase dynamic CT MRI Patients receive previous local therapy treatment ( RFA , PEI , cryoablation , surgery , resection ) eligible Age : 18 year 80 year ECOG Performance Status 0 2 ChildPugh class A ( ChildPugh score 56 ) Adequate bone marrow , liver function assess follow laboratory requirement conduct within 7 day prior screen : WBC count &gt; 2,000/mm3 Absolute neutrophil count &gt; 1,000/mm3 Hb ≧ 8.0 g/dL Platelet count ≧ 50,000 /mm3 Bilirubin ≦ 3 mg/dL Adequate clotting function : INR &lt; 2.3 &lt; 6sec ChildPugh score ≧ 7 ECOG Performance Status ≧ 3 Patients chronic kidney disease serum creatinine ≥ 1.2 mg/dL History organ allograft Patients uncontrolled comorbidity need treatment Patients receive prior systemic chemotherapy Patients extrahepatic metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>portal vein invasion</keyword>
	<keyword>transarterial chemoembolization</keyword>
	<keyword>transarterial chemoinfusion</keyword>
</DOC>